S. Greene and M. Gheorghiade, Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?, European Journal of Heart Failure, vol.309, issue.9, pp.875-878, 2015.
DOI : 10.1002/ejhf.335

S. Pocock, G. Calvo, J. Marrugat, K. Prasad, L. Tavazzi et al., International differences in treatment effect: do they really exist and why????, European Heart Journal, vol.34, issue.24, pp.1846-1852, 2013.
DOI : 10.1093/eurheartj/eht071

S. Kristensen, F. Martinez, P. Jhund, J. Arango, J. Be-?lohlávek et al., Geographic variations in the PARADIGM-HF heart failure trial, European Heart Journal, vol.37, issue.41, 2016.
DOI : 10.1093/eurheartj/ehw226

J. Mcmurray, M. Packer, A. Desai, J. Gong, M. Lefkowitz et al., Angiotensin???Neprilysin Inhibition versus Enalapril in Heart Failure, PARADIGM-HF Investigators and Committees, pp.993-1004, 2014.
DOI : 10.1056/NEJMoa1409077

S. Liggett, J. Mialet-perez, S. Thaneemit-chen, S. Weber, S. Greene et al., A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure, Proceedings of the National Academy of Sciences, vol.103, issue.30, pp.11288-11293, 2006.
DOI : 10.1073/pnas.0509937103

C. Laffer, F. Elijovich, G. Eckert, W. Tu, J. Pratt et al., Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans, Journal of the American Society of Hypertension, vol.8, issue.7, pp.475-480, 2014.
DOI : 10.1016/j.jash.2014.04.011

J. Ferreira, N. Girerd, P. Rossignol, and F. Zannad, Geographic differences in heart failure trials, European Journal of Heart Failure, vol.1, issue.9, pp.893-905, 2015.
DOI : 10.1002/ejhf.326

W. Stough, F. Zannad, B. Pitt, and S. Goldstein, Globalization of cardiovascular clinical research: The balance between meeting medical needs and maintaining scientific standards, American Heart Journal, vol.154, issue.2, pp.232-238, 2007.
DOI : 10.1016/j.ahj.2007.04.028

P. Rossignol and F. Zannad, Regional Differences in Heart Failure With Preserved Ejection Fraction Trials: When Nephrology Meets Cardiology but East Does Not Meet West, Circulation, vol.131, issue.1, pp.7-10, 2015.
DOI : 10.1161/CIRCULATIONAHA.114.013637

B. Pitt, M. Pfeffer, S. Assmann, R. Boineau, I. Anand et al., Spironolactone for Heart Failure with Preserved Ejection Fraction, New England Journal of Medicine, vol.370, issue.15, pp.1383-1392, 2014.
DOI : 10.1056/NEJMoa1313731

B. Pitt and M. Gheorghiade, Geographic variation in heart failure trials: time for scepticism?, European Journal of Heart Failure, vol.11, issue.6, pp.601-602, 2014.
DOI : 10.1002/ejhf.112

M. Gheorghiade, M. Vaduganathan, S. Greene, R. Mentz, K. Adams et al., Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions, Heart Failure Reviews, vol.58, issue.9, pp.135-152, 2014.
DOI : 10.1007/s10741-012-9361-8

K. Mahaffey, D. Wojdyla, K. Carroll, R. Becker, R. Storey et al., Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial, Circulation, vol.124, issue.5, pp.544-554, 2011.
DOI : 10.1161/CIRCULATIONAHA.111.047498

H. Wedel, D. Demets, P. Deedwania, B. Fagerberg, S. Goldstein et al., Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial, American Heart Journal, vol.142, issue.3, pp.502-511, 2001.
DOI : 10.1067/mhj.2001.117600

B. Ge, W. Peng, Y. Zhang, Y. Wen, C. Liu et al., Effectiveness of Valsartan/Amlodipine Single-pill Combination in Hypertensive Patients With Excess Body Weight, Journal of Cardiovascular Pharmacology, vol.66, issue.5, pp.497-503, 2015.
DOI : 10.1097/FJC.0000000000000301